Frequency of 5′IGH deletions in B-cell chronic lymphocytic leukemia

Cancer Genetics and Cytogenetics

Volumn 190, Issue 1, 2009, Pages 33-39

  Quintero Rivera, Fabiola ^a   Nooraie, Farzad ^a   Rao, P Nagesh ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5'IGH GENE; ADULT; AGED; ARTICLE; CHROMOSOME 13Q14 DELETION; CHROMOSOME DELETION; CHROMOSOME DELETION 17P; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN GENE; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TRISOMY 12; CHROMOSOME 12; CHROMOSOME ABERRATION; DNA FLANKING REGION; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETICS; KARYOTYPING; MIDDLE AGED; Y CHROMOSOME;

CD38 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN KINASE ZAP 70;

5' FLANKING REGION; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD38; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 12; CHROMOSOMES, HUMAN, Y; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, LEUKEMIC; GENE FREQUENCY; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 61349159400     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2008.12.004     Document Type: Article

References (33)

1. In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours (2001), IARC Press, Lyon
2. Juliusson G., and Gahrton G. Chromosome aberrations in B-cell chronic lymphocytic leukemia: pathogenetic and clinical implications. Cancer Genet Cytogenet 45 (1990) 143-160
3. Döhner H., Stilgenbauer S., Benner A., Leupolt E., Kröber A., Bullinger L., Döhner K., Bentz M., and Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343 (2000) 1910-1916
4. Dewald G.W., Brockman S.R., Paternoster S.F., Bone N.D., O'Fallon J.R., Allmer C., James C.D., Jelinek D.F., Tschumper R.C., Hanson C.A., Pruthi R.K., Witzig T.E., Call T.G., and Kay N.E. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 121 (2003) 287-295
5. Stilgenbauer S., and Döhner H. Molecular genetics and its clinical relevance. Hematol Oncol Clin North Am 18 (2004) 827-848 viii
6. Glassman A.B., and Hayes K.J. The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia. Cancer Genet Cytogenet 158 (2005) 88-91
7. H status and immunophenotyping. Leukemia 21 (2007) 2442-2451
8. Dyer M.J.S., and Oscier D.G. The configuration of immunoglobulin genes in B cell chronic lymphocytic leukemia. Leukemia 16 (2002) 973-984
9. Drandi D., Lee C., Dal Cin P., and Gribben J.G. Array-based comparative genomic hybridization identifies deletion. Array-based comparative genomic hybridization identifies deletion at 14q32 as a new prognostic marker in chronic lymphocytic leukemia (CLL). Abstract 649. Blood 102 11 (2003)
10. Fink S.R., Paternoster S.F., Smoley S.A., Flynn H.C., Geyer S.M., Shanafelt T.D., Lee Y.K., Jelinek D.F., Kay N.E., and Dewald G.W. Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemia. Leuk Res 29 (2005) 253-262
11. Wlodarska I., Matthews C., Veyt E., Pospisilova H., Catherwood M.A., Poulsen T.S., Vanhentenrijk V., Ibbotson R., Vandenberghe P., Morris T.C., and Alexander H.D. Telomeric IGH losses detectable by fluorescence in situ hybridization in chronic lymphocytic leukemia reflect somatic VH recombination events. J Mol Diagn 9 (2007) 47-54
12. H3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 99 (2002) 2262-2264
13. H3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood 107 (2006) 2889-2894
14. H3-72 B-cell chronic lymphocytic leukaemia (B-CLL). Leuk Res 30 (2006) 1197-1199
15. Tschumper R.C., Geyer S.M., Campbell M.E., Kay N.E., Shanafelt T.D., Zent C.S., Nowakowski G.S., Call T.G., Dewald G.W., and Jelinek D.F. Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients. J Clin Invest 118 (2008) 306-315
16. In: Shaffer L.G., and Tommerup N. (Eds). ISCN 2005: an international system for human cytogenetic nomenclature (2005) (2005), S. Karger, Basel
17. Gentleman R, Ihaka R, et al. R software environment, version 2.7.2. University of Auckland, New Zealand. (1997). Available at: http://www.r-project.org/.
18. Wiktor A., Rybicki B.A., Piao Z.S., Shurafa M., Barthel B., Maeda K., and Van Dyke D.L. Clinical significance of Y chromosome loss in hematologic disease. Genes Chromosomes and Cancer 27 (2000) 11-16
19. Matrai Z. CD38 as a prognostic marker in CLL. Hematology 10 (2005) 39-46
20. Deaglio S., Vaisitti T., Aydin S., Ferrero E., and Malavasi F. In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 108 (2006) 1135-1144
21. Monteserrat E. New prognostic markers in CLL. Hematology Am Soc Hematol Educ Program 2006 (2006) 279-284
22. Crespo M., Bosch F., Villamor N., Bellosillo B., Colomer D., Rozman M., Marcé S., López-Guillermo A., Campo E., and Montserrat E. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348 (2003) 1764-1775
23. Rassenti L.Z., Huynh L., Toy T.L., Chen L., Keating M.J., Gribben J.G., Neuberg D.S., Flinn I.W., Rai K.R., Byrd J.C., Kay N.E., Greaves A., Weiss A., and Kipps T.J. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351 (2004) 893-901
24. Aoun P., Blair H.E., Smith L.M., Dave B.J., Lynch J., Weisenburger D.D., Pavletic S.Z., and Sanger W.G. Fluorescence in situ hybridization detection of cytogenetic abnormalities in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma 45 (2004) 1595-1603
25. Schwaenen C., Nessling M., Wessendorf S., Salvi T., Wrobel G., Radlwimmer B., Kestler H.A., Haslinger C., Stilgenbauer S., Döhner H., Bentz M., and Lichter P. Automated array-based genomic profiling in chronic lymphocytic leukemia: Development of a clinical tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci USA 101 (2004) 1039-1044
26. Patel A., Kang S.H., Lennon P.A., Li Y.F., Rao P.N., Abruzzo L., Shaw C., Chinault A.C., and Cheung S.W. Validation of a targeted DNA microarray for the clinical evaluation of recurrent abnormalities in chronic lymphocytic leukemia. Am J Hematol 83 (2008) 540-546
27. Oscier D.G., Gardiner A.C., Mould S.J., Glide S., Davis Z.A., Ibbotson R.E., Corcoran M.M., Chapman R.M., Thomas P.W., Copplestone J.A., Orchard J.A., and Hamblin T.J. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100 (2002) 1177-1184
28. H mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100 (2002) 1410-1416
29. Deaglio S., Vaisitti T., Bergui L., Bonello L., Horenstein A.L., Tamagnone L., Boumsell L., and Malavasi F. CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood 105 (2005) 3042-3050
30. Rawstron A.C., Green M.J., Kuzmicki A., Kennedy B., Fenton J.A., Evans P.A., O'Connor S.J., Richards S.J., Morgan G.J., Jack A.S., and Hillmen P. Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood 100 (2002) 635-639
31. Rosenwald A., Alizadeh A.A., Widhopf G., Simon R., Davis R.E., Yu X., Yang L., Pickeral O.K., Rassenti L.Z., Powell J., Botstein D., Byrd J.C., Grever M.R., Cheson B.D., Chiorazzi N., Wilson W.H., Kipps T.J., Brown P.O., and Staudt L.M. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194 (2001) 1639-1647
32. Grever M.R., Lucas D.M., Dewald G.W., Neuberg D.S., Reed J.C., Kitada S., Flinn I.W., Tallman M.S., Appelbaum F.R., Larson R.A., Paietta E., Jelinek D.F., Gribben J.G., and Byrd J.C. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 25 (2007) 799-804
33. Schroeder Jr. H.W., and Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today 15 (1994) 288-294